|1.||Samnick, Samuel: 2 articles (01/2007 - 05/2006)|
|2.||Kirsch, Carl-Martin: 2 articles (01/2007 - 05/2006)|
|3.||Fozing, Thierry: 2 articles (01/2007 - 05/2006)|
|4.||Wagner, Mathias: 1 article (01/2007)|
|5.||Menger, Michael D: 1 article (01/2007)|
|6.||Nestle, Ursula: 1 article (01/2007)|
|7.||Schaefer, Andrea: 1 article (01/2007)|
|1.||Prostatic Neoplasms (Prostate Cancer)
01/01/2007 - "These results suggest that ITIC(OH) is a promising candidate as radiotracer for detecting prostate cancer and warrants further studies in patients to ascertain its potential as an imaging agent for clinical use."
01/01/2007 - "This study evaluates the potential of 8-[123I]iodo-1,2,3,4-tetrahydro-7-hydroxyisoquinoline-3-carboxylic acid [ITIC(OH)] as an imaging agent for prostate cancer in experimental models of human prostate cancer. "
01/01/2007 - "Thereafter, ITIC(OH) was examined in CD-1 nu/nu mice engrafted with human PC-3 and DU-145 prostate cancer in the flank or orthotopically in the prostate. "
05/01/2006 - "ITIC(OH) accumulated intensively in primary human prostate cancer cells. "
05/01/2006 - "In conclusion, the specific and high-level accumulation of ITIC(OH) in human prostate carcinoma cells, indicates that the new radiopharmaceutical is a good candidate for further in vivo investigations to ascertain its potential as an imaging probe for prostate cancer by SPET."
01/01/2007 - "In vivo, ITIC(OH) accumulated highly and specifically in tumors, reaching 13.6+/-2.1% to 16.2+/-2.5% injected dose per gram (ID/g) in heterotopic tumors compared with 14.8+/-2.6% and 17.6+/-3.4% ID/g in orthotopic tumor engrafts at 60 and 240 min postinjection, respectively. "
01/01/2007 - "Bioevaluation involved examination of the in vivo stability and uptake characteristics of ITIC(OH) into tumors and different organs by dynamic in vivo analysis and gamma counting of organs of interest after dissection. "
05/01/2006 - "Thereafter, ITIC(OH) was evaluated in terms of its uptake in primary human PC-3 and DU-145 prostate cancer cells, followed by analysis of the underlying mechanisms of the radioactivity accumulation in tumor cells. "
05/01/2006 - "This work describes the synthesis and tumor affinity testing of 8-[123I]iodo-l-1,2,3,4-tetrahydro-7-hydroxyisoquinoline-3-carboxylic acid [ITIC(OH)], a cyclic non-naturally occurring amino acid as an imaging probe for prostate cancer. "
05/01/2006 - "Inhibition experiments revealed that ITIC(OH) was taken up into tumor by an active transport different from the common amino acid carrier systems, including the sodium-dependent system A and B+,0, and the sodium-independent L- and ASC-type transporter. "